Abattis Announces Appointment of Raymond Cox, Andrea Bates & Barry Comis
September 4, 2015 (Source: Abattis Bioceuticals Corp.) — Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTCQX: ATTBF) (CSE: ATT), is a Company that develops and commercializes natural health (nutraceutical) products. Abattis conducts research and development to create plant-based (botanical) intellectual property, and ingredients for the pharmaceutical, nutraceutical, bioceutical and cosmetic markets; some of which will contain cannabinoid compounds.
We would like to take this opportunity to announce the following resignations and appointments within the Company and its wholly owned subsidiaries.
The appointment of Raymond Cox as President of Vergence Visionary Bioceuticals Corp. (“Vergence”) effective September 1, 2015. Mr.Cox is an entrepreneur, visionary, start up, sales and marketing leader for 20 years in “the direct to consumer and wellness industries”. He has successfully changed 3 Canadian hair loss clinics in a positive direction. They have grown to become 13 profitable International hair loss and hair removal clinics, which ultimately produced millions of dollars in yearly revenue within 36 months. Furthermore, he has personally built online wellness organizations into the 10’s of thousands and influenced 100’s of thousands through training, motivation and collaboration with key medical personnel.
Andrea Bates will be joining the team as the Chief Operating Officer of Vergence. Mrs. Bates, as co-founder of 10 Thousand BC(r) Inc. has helped lead the research, team management, product marketing, brand development and design packaging. Her marketing and branding expertise has been an asset in website development, presentation materials, research and industry relations. As CMO, Andrea directs and provides communication of corporate vision, product branding and development to the marketing and advertising team. She is also involved in sales, export market development and corporate planning.
Her energetic marketing vision was instrumental in the development and launch of 10 Thousand BC(r) Luxury Glacier Water. Twenty-one days after the launch at the Sundance Film Festival, 10 Thousand BC(r) appeared on ABC News Good Morning America to an audience of 5.36M and was instantly positioned as a top luxury brand. Since then 10 Thousand BC(r) has appeared in numerous magazines, TV Shows and Movies with virtually no advertising dollars spent!
Mr. Barry Comis was appointed to the Board of Directors of Abattis effective September 1, 2015.
Get our daily investorintel update
Mr. Comis has spent the last eight years as Executive CP at Viero Group Ltd, where he remains in charge of Corporate Investment Capital and Corporate business consulting; specializing in offshore Fund management and investment acquisitions and mergers. Mr. Comis is also the current owner and principal of Pure Logic Technologies Ltd., which is a 3d discrete event simulation company that models large industrial plants or assists in the design of new operations.
Mr. Brazos Minshew will be resigning as President of Biocell Labs Inc. (“Biocell”) and Vergence as well as Chief Science Officer for Abattis. Mr. Minshew, however will not be leaving the Company. He will be assuming his new role on the Board of Directors of Abattis, all effective August 31, 2015.
Emanuel Montenegrino will also be resigning effective August 31, 2015 as a Director of the Company. The Company would like to thank Mr. Montenegrino for all his services and wishes him the best in all his future endeavors.
About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company that aggregates, incubates, integrates, and invests in the botanical drug development industry. The Company develops and licenses natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets – some of which will contain cannabinoid compounds. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at:www.abattis.com.
ON BEHALF OF THE BOARD
Bill Fleming, CEO
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.
Raj Shah has professional experience working for over a half a dozen years at financial firms such as Merrill Lynch and First Allied Securities Inc., ... <Read more about Raj Shah>